| __timestamp | Apellis Pharmaceuticals, Inc. | Viking Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 2908166 | 1244910 |
| Thursday, January 1, 2015 | 6356782 | 5029636 |
| Friday, January 1, 2016 | 4303743 | 4846776 |
| Sunday, January 1, 2017 | 10463151 | 5329003 |
| Monday, January 1, 2018 | 22639184 | 7121000 |
| Tuesday, January 1, 2019 | 67046483 | 9128000 |
| Wednesday, January 1, 2020 | 139401000 | 10731000 |
| Friday, January 1, 2021 | 176771000 | 10701000 |
| Saturday, January 1, 2022 | 277163000 | 16121000 |
| Sunday, January 1, 2023 | 500815000 | 37021000 |
Unleashing the power of data
In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for financial health. Apellis Pharmaceuticals, Inc. and Viking Therapeutics, Inc. offer a fascinating case study in cost optimization from 2014 to 2023. Over this period, Apellis saw a staggering increase in SG&A expenses, peaking at $500 million in 2023, a 17,000% rise from 2014. In contrast, Viking's expenses grew more modestly, reaching $37 million in 2023, marking a 2,900% increase. This stark difference highlights Apellis's aggressive expansion strategy, while Viking maintains a more conservative approach. Understanding these trends provides valuable insights into each company's operational priorities and market strategies. As investors and industry watchers analyze these figures, the question remains: which strategy will yield better long-term returns?
Who Optimizes SG&A Costs Better? Merck & Co., Inc. or Viking Therapeutics, Inc.
AstraZeneca PLC vs Viking Therapeutics, Inc.: SG&A Expense Trends
Breaking Down SG&A Expenses: Amgen Inc. vs Viking Therapeutics, Inc.
Takeda Pharmaceutical Company Limited vs Apellis Pharmaceuticals, Inc.: SG&A Expense Trends
Comparing SG&A Expenses: argenx SE vs Apellis Pharmaceuticals, Inc. Trends and Insights
Cost Management Insights: SG&A Expenses for Neurocrine Biosciences, Inc. and Viking Therapeutics, Inc.
Comparing SG&A Expenses: Catalent, Inc. vs Viking Therapeutics, Inc. Trends and Insights
Ionis Pharmaceuticals, Inc. vs Apellis Pharmaceuticals, Inc.: SG&A Expense Trends
Apellis Pharmaceuticals, Inc. and ImmunityBio, Inc.: SG&A Spending Patterns Compared
Apellis Pharmaceuticals, Inc. or Soleno Therapeutics, Inc.: Who Manages SG&A Costs Better?
Cost Management Insights: SG&A Expenses for Apellis Pharmaceuticals, Inc. and Evotec SE
Viking Therapeutics, Inc. and Perrigo Company plc: SG&A Spending Patterns Compared